Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase β

被引:83
作者
Canitrot, Y
Lautier, D
Laurent, G
Fréchet, M
Ahmed, A
Turhan, AG
Salles, B
Cazaux, C
Hoffmann, JS
机构
[1] CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France
[2] Inst Claudius Regaud, INSERM, F-31052 Toulouse, France
[3] Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France
关键词
bcr-abl; mutator phenotype; DNA polymerase beta;
D O I
10.1038/sj.onc.1202619
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome resulting from the translocation t(9-22) producing the chimeric 190 and 210 kDa BCR-ABL fusion proteins. Evolution of the CML to the more aggressive acute myelogenous leukemia (AML) is accompanied by increased cellular proliferation and genomic instability at the cytogenetic level. We hypothezised that genomic instability at the nucleotide level and spontaneous error in DNA replication may also contribute to the evolution of CML to AML. Murine Ba/F3 cell line was transfected with the p190 and p210-encoding BCR-ABL oncogenes, and spontaneous mutation frequency at the Na-K-ATPase and the hypoxanthine guanine phosphoribosyl transferase (HPRT) loci were measured. A significant 3-5-fold increase in mutation frequency for the transfected cells relative to the untransfected control cells was found. Furthermore, we observed that BCR-ABL transfection induced an overexpression of DNA polymerase beta, the most inaccurate of the mammalian DNA polymerases, as well as an increase in its activity, suggesting that inaccuracy of DNA replication may account for the observed mutator phenotype. These data suggest that the Philadelphia abnormality confers a mutator phenotype and may have implications for the potential role of DNA polymerase beta in this process.
引用
收藏
页码:2676 / 2680
页数:5
相关论文
共 30 条
  • [1] BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line
    Ahmed, M
    Dusanter-Fourt, I
    Bernard, M
    Mayeux, P
    Hawley, RG
    Bennardo, T
    Novault, S
    Bonnet, ML
    Gisselbrecht, S
    Varet, B
    Turhan, AG
    [J]. ONCOGENE, 1998, 16 (04) : 489 - 496
  • [2] ALTERATIONS IN THE P53 GENE AND THE CLONAL EVOLUTION OF THE BLAST CRISIS OF CHRONIC MYELOCYTIC-LEUKEMIA
    AHUJA, H
    BARELI, M
    ADVANI, SH
    BENCHIMOL, S
    CLINE, MJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (17) : 6783 - 6787
  • [3] THE SPECTRUM OF MOLECULAR ALTERATIONS IN THE EVOLUTION OF CHRONIC MYELOCYTIC-LEUKEMIA
    AHUJA, H
    BARELI, M
    ARLIN, Z
    ADVANI, S
    ALLEN, SL
    GOLDMAN, J
    SNYDER, D
    FOTI, A
    CLINE, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) : 2042 - 2047
  • [4] BERNSTEIN R, 1988, SEMIN HEMATOL, V25, P20
  • [5] Bouayadi K, 1997, CANCER RES, V57, P110
  • [6] Mutations of mitotic checkpoint genes in human cancers
    Cahill, DP
    Lengauer, C
    Yu, J
    Riggins, GJ
    Willson, JKV
    Markowitz, SD
    Kinzler, KW
    Vogelstein, B
    [J]. NATURE, 1998, 392 (6673) : 300 - 303
  • [7] Overexpression of DNA polymerase β in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs
    Canitrot, Y
    Cazaux, C
    Fréchet, M
    Bouayadi, K
    Lesca, C
    Salles, B
    Hoffmann, JS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) : 12586 - 12590
  • [8] COLLINS SJ, 1989, BLOOD, V73, P1028
  • [9] COPELAND WC, 1992, J BIOL CHEM, V267, P21459
  • [10] P53 IN CHRONIC MYELOGENOUS LEUKEMIA IN ACUTE PHASE
    FEINSTEIN, E
    CIMINO, G
    GALE, RP
    ALIMENA, G
    BERTHIER, R
    KISHI, K
    GOLDMAN, J
    ZACCARIA, A
    BERREBI, A
    CANAANI, E
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (14) : 6293 - 6297